Exelixis (NASDAQ: EXEL) recently received a number of ratings updates from brokerages and research firms:
- 10/4/2024 – Exelixis had its price target raised by analysts at Royal Bank of Canada from $27.00 to $30.00. They now have an “outperform” rating on the stock.
- 9/26/2024 – Exelixis had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $27.00 price target on the stock.
- 9/20/2024 – Exelixis had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $29.00 price target on the stock.
- 9/19/2024 – Exelixis is now covered by analysts at UBS Group AG. They set a “neutral” rating and a $30.00 price target on the stock.
- 9/18/2024 – Exelixis had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $29.00 price target on the stock.
Exelixis Stock Performance
Shares of EXEL stock traded down $0.20 during trading hours on Thursday, hitting $25.23. The company had a trading volume of 85,269 shares, compared to its average volume of 1,990,133. Exelixis, Inc. has a 12 month low of $18.64 and a 12 month high of $27.83. The firm has a market capitalization of $7.65 billion, a price-to-earnings ratio of 39.42, a PEG ratio of 0.56 and a beta of 0.54. The firm’s fifty day moving average is $26.06 and its 200 day moving average is $23.64.
Exelixis (NASDAQ:EXEL – Get Free Report) last released its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.44. The business had revenue of $637.18 million for the quarter, compared to analyst estimates of $468.21 million. Exelixis had a return on equity of 15.54% and a net margin of 17.38%. On average, sell-side analysts expect that Exelixis, Inc. will post 1.59 EPS for the current fiscal year.
Insider Buying and Selling at Exelixis
Institutional Investors Weigh In On Exelixis
Institutional investors have recently made changes to their positions in the company. LSV Asset Management raised its position in Exelixis by 1,651.4% during the first quarter. LSV Asset Management now owns 2,774,707 shares of the biotechnology company’s stock valued at $65,844,000 after purchasing an additional 2,616,278 shares in the last quarter. Hsbc Holdings PLC boosted its position in shares of Exelixis by 45.3% during the 2nd quarter. Hsbc Holdings PLC now owns 90,211 shares of the biotechnology company’s stock worth $2,031,000 after purchasing an additional 28,126 shares in the last quarter. Farallon Capital Management LLC boosted its position in shares of Exelixis by 1.6% during the 2nd quarter. Farallon Capital Management LLC now owns 27,102,500 shares of the biotechnology company’s stock worth $608,993,000 after purchasing an additional 424,000 shares in the last quarter. Los Angeles Capital Management LLC boosted its position in shares of Exelixis by 948.3% during the 1st quarter. Los Angeles Capital Management LLC now owns 2,454,277 shares of the biotechnology company’s stock worth $58,240,000 after purchasing an additional 2,220,150 shares in the last quarter. Finally, Intech Investment Management LLC boosted its position in shares of Exelixis by 155.8% during the 1st quarter. Intech Investment Management LLC now owns 100,039 shares of the biotechnology company’s stock worth $2,374,000 after purchasing an additional 60,925 shares in the last quarter. Institutional investors own 85.27% of the company’s stock.
Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Featured Articles
- Five stocks we like better than Exelixis
- Canadian Penny Stocks: Can They Make You Rich?
- Top 2 Analyst Picks: Stocks Poised for Double-Digit Growth
- What is a Dividend King?
- These 3 Stocks Are Screaming Oversold: Seize the Opportunity
- 3 Best Fintech Stocks for a Portfolio Boost
- Stryker’s Acquisition Spree: Double-Digit Growth on the Horizon
Receive News & Ratings for Exelixis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc and related companies with MarketBeat.com's FREE daily email newsletter.